Best Practices

Is Your Practice Biosimilar Ready?

Publish date: May 9, 2017
This article was funded and directed by Janssen Biotech, Inc. The editors and staff of Rheumatology News were not involved in the writing or review of this supplement.

 

Click Here to Read the Full Supplement.

Topics include:

  • The Pathway for Biosimilar Approval
  • The Difference between Biosimilars and Generics
  • Draft Interchangeablity Guidelines
  • ACR Position Statement on Biosimilars
  • Effect of the Reimbursement Model on Biosimilars

Click Here to Read the Full Supplement.

Next Article:

Restoring the promise of (really) meaningful use